CTCs and Novel Target Bio-marker Analysis for Prediction and Monitoring of Metastasis/Recurrence in Post-surgery Colorectal Cancer Patients Using MiSelect R Rare Cell System

Circulating Tumor Cells, CTC Clinical Trial

Official title:

CTCs and Novel Target Bio-marker Analysis for Prediction and Monitoring of Metastasis/Recurrence in Post-surgery Colorectal Cancer Patients Using MiSelect R Rare Cell System

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03013868
• Other study ID #: MiC-SRS-CRC-001
• Status: Recruiting
• Start date: October 2016
• Est. completion date: February 2021

Study information

• Verified date: May 2018
• Source: MiCareo Taiwan Co., Ltd.
• Contact: Wang Henry, Master
• Phone: 886-2-2796-5096
• Email: henrywang[@]micareo.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Despite the growing public awareness and recent progress in multimodality therapy to the colorectal cancer (CRC), CRC still ranks high on the list of the most common and deadly cancers in Taiwan. The cause of CRC mortality is due mainly to the occurrence of distant metastasis. Several reports suggested that circulating tumor cells (CTCs) highly associated with metastasis suggesting that targeting CTCs may offer an unprecedented opportunity to prevent the development of metastasis. Early detection and characterization of CTCs is therefore important as a potential strategy to monitor the progression of CRC. The current proposal is focused on detecting CTCs from peripheral blood of CRC patients using Miselect R system. We will monitor the amount of CTCs and correlate with CRC progression and prognosis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: February 2021
• Est. primary completion date: December 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 90 Years

Eligibility

Inclusion Criteria:

1. Over 20 and less than 90 years of age.

2. Colorectal cancer stage II/III patients who will undergo surgical resection.

3. Subject having agreed to participate in the study and follow the study procedures by providing written informed consent prior entering the study.

Exclusion Criteria:

1. Have other cancer history.

2. Subject being identified with any blood borne infectious disease

Related Conditions & MeSH terms

• Circulating Tumor Cells, CTC
• Colorectal Neoplasms
• Neoplastic Cells, Circulating
• Recurrence

Locations

Country	Name	City	State
Taiwan	Taipei Veterans General Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
MiCareo Taiwan Co., Ltd.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease Free Survival		5 years